Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465557 | 1.00 | TAAR1 (1.00) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| Bromide SCHEMBL3284467 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| Bromide SCHEMBL30626448 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| Hydrochloric Acid SCHEMBL31505864 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| Hydrochloric Acid SCHEMBL453247 | 0.98 | TAAR1 (0.96) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| Phenol SCHEMBL28853303 | 0.92 | TAAR1 (0.85) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| SCHEMBL30012454 | 0.87 | DRD2 (0.77) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| SCHEMBL632444 | 0.87 | DRD2 (0.77) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| SCHEMBL723832 | 0.85 | DRD2 (0.74) | TAAR1DRD2DRD1ENPP2CHRM2 | |
| SCHEMBL3292837 | 0.85 | DRD2 (0.74) | TAAR1DRD2DRD1ENPP2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| CN-119041239-B | Preparation process of thermosensitive coating and thermosensitive paper | 江苏金大包装材料科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119331550-A | Low-dielectric chip mounting adhesive film composition and adhesive film | 北京序轮科技有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-119041239-A | Preparation process of thermosensitive coating and thermosensitive paper | 江苏金大包装材料科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-10-31 | — | — | US | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| EP-4392037-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Boyce Thompson Institute for Plant Research Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| EP-1438053-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-21 | — | — | EP | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| WO-2003032997-A1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | claimed |
| US-6346402-B1 | ACTS ON OPTICALLY ACTIVE (S)-ALPHA-PHENETHYLAMINE AND PYRUVIC ACID TO FORM ACETOPHENONE AND ALANINE; FOR PRODUCING CHEMICAL INTERMEDIATES OF DRUGS AND AGRICULTURAL CHEMICALS | KANEKA CORPORATION (JP) | 2002-02-12 | — | — | US | claimed |
| EP-1045025-A1 | (S)-alpha-PHENETHYLAMINE : PYRUVATE TRANSAMINASE | KANEKA CORPORATION (JP) | 2000-10-18 | — | — | EP | claimed |
| CN-1150178-A | Peroxidase or hydrogen peroxide testing method and testing reagent | JEOL LTD (JP) | 1997-05-21 | — | — | CN | claimed |
| WO-1996019433-A1 | PROCESS FOR PREPARING ACETOXYSTYRENE | HOECHST CELANESE CORPORATION (US) | 1996-06-27 | — | — | WO | claimed |
| EP-0517345-B1 | Intermediates of the mureidomycin group, their preparation, and their use | SANKYO CO (JP) | 1995-07-19 | — | — | EP | claimed |
| EP-0517345-A1 | Intermediates of the mureidomycin group, their preparation, and their use | SANKYO COMPANY LIMITED (JP) | 1992-12-09 | — | — | EP | claimed |
| US-4242355-A | Novel 3-(aminoethyl)-phenols | ROUSSEL UCLAF (FR) | 1980-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | TAAR1 3452/4885DRD2 4882/4885DRD1 4883/4885 |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | MAG, PMP22, B3GAT3 | TAAR1 4682/4885DRD2 4814/4885DRD1 4874/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | TAAR1 3718/4885DRD2 4879/4885DRD1 4882/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | TAAR1 498/4885DRD2 4752/4885DRD1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.